Edgen Stock·Sep 29 2025, 12:45戻る
戻る
FDA Approval Bolsters Precision Oncology for Advanced Breast Cancer
Edgen Stock·Sep 29 2025, 12:45
[1] FDA Approves Guardant360® CDx as Companion Diagnostic for Eli Lilly and Company’s Inluriyo™ (imlunestrant) for Treatment of ESR1-mutated Advanced Breast Cancer[2] FDA approves Guardant360 CDx as companion diagnostic for breast cancer drug[3] FDA approves Lilly's Inluriyo for ESR1-mutated breast cancer - Investing.com